Nuravax
PrivateLast Round
Grant
May 5, 2025
Total Funding Raised
$3M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Nuravax is a biotechnology company that engineers precision immunotherapies to prevent and cure Alzheimer's and Parkinson's diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2G
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuravax Comparables
Compare Nuravax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vaxxinity, Inc. | 79% | |
| Axon Neuroscience | 78% | |
| Grifols | 77% | |
Nuravax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 5, 2025 |
Nuravax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
Monthly visitors grew 150% MoM, reaching 1.6K.
- Jan 29, 2026
Monthly visitors grew 216% MoM, reaching 1.2K.
Nuravax Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nuravax's valuation, stock price, and market status.